NRAS and mucinous adenocarcinoma: Mucinous adenocarcinoma was more common in tumors with BRAF/NRAS mutations (two of six cases, 33.3%) compared with KRAS-mutated tumors (six of 39 cases, 15.4%) or WT tumors (two of 27 cases, 7.4%).